Eutylone (also known as β-keto-1,3-benzodioxolyl-N-ethylbutanamine, bk-EBDB, and N-ethylbutylone) is a
stimulant and
empathogenic compound developed in the 1960s,[3][4] which is classified as a
designer drug.[5] It was first reported to the
EMCDDA in 2014 and became widespread internationally in 2019-2020 following bans on the related compound
ephylone.[6][7][8][9] It is a synthetic cathinone.[9] In 2021, eutylone was the most common cathinone identified by the Drug Enforcement Administration in the United States.[10]
Legal status
Sweden's public health agency suggested classifying eutylone as a hazardous substance, on September 25, 2019.[11]
^Chen HY, Chien WC, Huang MN, Fang CC, Weng TI (January 2021). "Analytically confirmed eutylone (bk-EBDB) exposure in emergency department patients". Clinical Toxicology. 59 (9): 846–848.
doi:
10.1080/15563650.2020.1868491.
PMID33448882.
S2CID231611658.
^
abNakamura M, Takaso M, Takeda A, Hitosugi M (September 2022). "A fatal case of intoxication from a single use of eutylone: Clinical symptoms and quantitative analysis results". Leg Med (Tokyo). 58: 102085.
doi:
10.1016/j.legalmed.2022.102085.
PMID35537301.
S2CID248602483.